Aurobindo Pharma Subsidiary Launches Generic Pomalidomide Capsules in U.S. Market

Aurobindo Pharma's wholly owned subsidiary, Eugia Pharma Specialities, has launched generic Pomalidomide Capsules in the U.S. market in four strengths (1 mg to 4 mg). The product, a generic equivalent of BMS Pharmaceuticals' Pomalyst, treats relapsed or refractory multiple myeloma and AIDS-related Kaposi sarcoma. Eugia was among the first-to-file ANDA applicants, with manufacturing at its Unit-I. The U.S. market for Pomalidomide capsules is estimated at approximately US$3.3 billion for the year ending January 2026.